KalVista Pharmaceuticals (NASDAQ:KALV) Trading Down 6.2%

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) shares were down 6.2% on Tuesday . The company traded as low as $31.47 and last traded at $34.00. Approximately 1,123,260 shares were traded during trading, a decline of 27% from the average daily volume of 1,537,545 shares. The stock had previously closed at $36.25.

A number of equities research analysts have weighed in on KALV shares. Stifel Nicolaus lifted their price target on shares of KalVista Pharmaceuticals from $30.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday, February 9th. Needham & Company LLC lifted their price target on shares of KalVista Pharmaceuticals from $25.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, January 26th. Jefferies Financial Group lifted their price objective on shares of KalVista Pharmaceuticals from $34.00 to $61.00 and gave the company a “buy” rating in a report on Tuesday, February 9th. Zacks Investment Research cut shares of KalVista Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 10th. Finally, Roth Capital boosted their price target on shares of KalVista Pharmaceuticals from $30.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, February 17th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. KalVista Pharmaceuticals has an average rating of “Buy” and an average price target of $44.86.

The firm has a market cap of $610.03 million, a PE ratio of -16.31 and a beta of 2.13. The firm’s 50-day moving average price is $22.38 and its two-hundred day moving average price is $17.31.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Wednesday, December 9th. The specialty pharmaceutical company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.09. KalVista Pharmaceuticals had a negative net margin of 229.45% and a negative return on equity of 47.45%. On average, research analysts expect that KalVista Pharmaceuticals, Inc. will post -2.67 EPS for the current year.

Large investors have recently modified their holdings of the company. FMR LLC purchased a new stake in KalVista Pharmaceuticals in the 1st quarter valued at $21,036,000. BlackRock Inc. raised its position in KalVista Pharmaceuticals by 21.7% in the 4th quarter. BlackRock Inc. now owns 1,113,380 shares of the specialty pharmaceutical company’s stock valued at $21,143,000 after purchasing an additional 198,646 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in KalVista Pharmaceuticals in the 4th quarter valued at $939,000. Asymmetry Capital Management L.P. purchased a new stake in KalVista Pharmaceuticals in the 4th quarter valued at $891,000. Finally, Koshinski Asset Management Inc. purchased a new stake in KalVista Pharmaceuticals in the 4th quarter valued at $312,000. Institutional investors and hedge funds own 90.19% of the company’s stock.

KalVista Pharmaceuticals Company Profile (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

See Also: Analyst Ratings Trading

Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.